A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| AZD-3409 | AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. AZD3409 might be active in gefitinib-resistant breast carcinoma. Synonyms: AZD-3409; AZD 3409; AZD3409. Grade: 98%. CAS No. 345915-10-8. Molecular formula: C34H41FN4O4S2. Mole weight: 652.844. |  |
| AZD-3463 | AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity. Synonyms: AZD 3463; AZD3463. Grade: 0.98. CAS No. 1356962-20-3. Molecular formula: C24H25ClN6O. Mole weight: 448.95. | |
| AZD-3463 | AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ALK/IGF1R inhibitor. CAS No. 1356962-20-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15609. |  |
| AZD3514 | AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC50 value of 5.75. AZD3514 can be used for the research of prostate cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1240299-33-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16079. | |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Synonyms: AZD3514; AZD 3514; AZD-3514. Grade: 0.98. CAS No. 1240299-33-5. Molecular formula: C25H32F3N7O2. Mole weight: 519.56. | |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1, 2, 4]triazolo[4, 3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Group: Biochemicals. Alternative Names: 1- (4- (2- (4- (1- (3- (trifluoromethyl) -7, 8-dihydro-[1, 2, 4]triazolo[4, 3-b]pyridazin-6-yl) piperidin-4-yl) phenoxy) ethyl) piperazin-1-yl) ethanone; 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine. Grades: Highly Purified. CAS No. 1240299-33-5. Pack Sizes: 10mg, 25mg. Molecular Formula: C25H32F3N7O2, Molecular Weight: 519.56. US Biological Life Sciences. |  Worldwide |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Synonyms: AZD3759; AZD-3759; AZD 3759. Grade: 98%. CAS No. 1626387-80-1. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. | |
| AZD-3759 hydrochloride | AZD-3759 hydrochloride is an effective, orally active and central nervous system-penetrant EGFR inhibitor. AZD-3759 hydrochloride induces cancer cell apoptosis. Synonyms: AZD3759 hydrochloride; Zorifertinib HCl; Zorifertinib hydrochloride; (R)-4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride. CAS No. 1626387-81-2. Molecular formula: C22H24Cl2FN5O3. Mole weight: 496.36. | |
| AZD3839 | AZD3839, also called CHEMBL2177913, as a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the inhibition of BACE1 impedes the production of Aβ peptide. Synonyms: AZD3839; AZD-3839; AZD 3839. (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine; CHEMBL2177913; I8ID590133; UNII-I8ID590133; I8ID590133; SCHEMBL1358337; BDBM50398264; (1S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine; 1227163-84-9; 1H-Isoindol-3-amine, 1-(2-(difluoromethyl)-4-pyridinyl)-4-fluoro-1-(3-(5-pyrimidinyl)phenyl)-, (1S)-. CAS No. 1227163-84-9. Molecular formula: C24H16F3N5. Mole weight: 431.41. | |
| AZD3839 free base | AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1227163-84-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-13438. | |
| AZD3965 | AZD3965 is a potent, selective and orally available monocarboxylate transporter 1 (MCT1) inhibitor with a binding affinity of 1.6 nM, 6-fold selective over MCT2. Phase 1. Group: Inhibitors. CAS No. 1448671-31-5. Pack Sizes: 5mg. Product ID: S7339. Formula: C21H24F3N5O5S. Smiles: CC1=C(C(=NN1)C(F)(F)F)CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)C(C)C)C(=O)N4CC(CO4)(C)O. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| AZD3965 | AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, which is 6-fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose- and time-dependent accumulation of lactate in the tumors, suppresses tumor growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine. The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers a novel mechanism for targeting the metabolic phenotype in tumors that preferentially express MCT1. Synonyms: (S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione; AZD3965; AZD-3965; AZD 3965. Grade: >98%. CAS No. 1448671-31-5. Molecular formula: C21H24F3N5O5S. Mole weight: 515.51. | |
| AZD3965 | AZD3965 Inhibitor. Uses: Scientific use. Product Category: T3210. CAS No. 1448671-31-5. |  |
| AZD3965 | AZD3965 is a selective MCT1 inhibitor with a Ki of 1.6 nM, showing 6-fold selectivity over MCT2. Uses: Scientific research. Category: Signaling pathways. CAS No. 1448671-31-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-12750. | |
| AZD3988 | AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC50 value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 892489-52-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50861. | |
| AZD 3988 | AZD 3988 is a selective and potent diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor with IC50 value of 0.6 nM. It is selective for DGAT-1 over DGAT-2, cytochrome P450 enzymes and Kv11.1 (hERG). It suppresses adipose tissue TAG synthesis and triacylglyceride (TAG) plasma excursion in rats. It reduces body weight of diet-induced obese rats and may be used as a potential treatment for diabetes and other metabolic diseases. It is orally bioavailable and cell permeable. Synonyms: AZD 3988; AZD-3988; AZD3988; trans-4-[-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid. Grade: ≥98% by HPLC. CAS No. 892489-52-0. Molecular formula: C23H22F2N4O4. Mole weight: 456.44. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable 11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Synonyms: AZD-4017; AZD 4017; (S)-2-(1-(5-(Cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid. Grade: 96%. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. | |
| AZD 4017 | AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC50 of 7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1024033-43-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18053. | |
| AZD4144 | AZD4144 is an orally active NLRP3 inhibitor (EC50: 0.082 μM). AZD4144 effectively inhibits the release of IL-1β when NLRP3 is overactivated, exerting an anti-inflammatory effect. AZD4144 has low inhibitory effect on hERG and low cardiotoxicity. AZD4144 has the potential to study diseases and conditions associated with NLRP3 inflammasome activation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2890191-41-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-162877. | |
| AZD4320 | AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1357576-48-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112416. | |
| AZD-4320 | AZD-4320 is a new type of BH3 analogue BCL2/BCLxL dual inhibitor. Synonyms: AZD4320. Grade: ≥98% by HPLC. CAS No. 1357576-48-7. Molecular formula: C45H48ClF3N4O7S3. Mole weight: 945.5. | |
| AZD-4547 | AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Synonyms: AZD-4547; AZD 4547; AZD4547; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide. Grade: 98%. CAS No. 1035270-39-3. Molecular formula: C26H33N5O3. Mole weight: 463.582. | |
| AZD4547 (Fexagratinib) | Fexagratinib (AZD4547,ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3. Group: Inhibitors. Alternative Names: ABSK 091. CAS No. 1035270-39-3. Pack Sizes: 5mg. Product ID: S2801. Formula: C26H33N5O3. Smiles: CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD4573 | AZD4573 is a potent inhibitor of CDK9 (IC50 of 1/2 = 16 min) and high selectivity versus other kinases, including other CDK family kinases. Group: Inhibitors. CAS No. 2057509-72-3. Pack Sizes: 2mg. Product ID: S8719. Formula: C22H28ClN5O2. Smiles: CC(=O)NC1CCCC(C1)C(=O)NC2=NC=C(C(=C2)C3=C4CC(CN4N=C3)(C)C)Cl. Storage Conditions: 3 years -20°C powder. | United States; Europe |
| AZD4573 | AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases. AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. Synonyms: AZD-4573; AZD 4573; (1S,3R)-3-acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexane-1-carboxamide. Grade: ≥98%. CAS No. 2057509-72-3. Molecular formula: C22H28ClN5O2. Mole weight: 429.94. | |
| AZD4573 | AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2057509-72-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112088. | |
| AZD-4635 | AZD-4635 is an orally available adenosine 2A receptor (A2AR) inhibitor. Synonyms: AZD-4635; AZD 4635; AZD4635; HTL-1071; HTL 1071; HTL1071; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine. CAS No. 1321514-06-0. Molecular formula: C15H11ClFN5. Mole weight: 315.736. | |
| AZD-4694 | AZD-4694 is a bio-active chemical compound and is used as a diagnostic imaging agent. It was developed by AstraZeneca. Synonyms: AZD 4694; AZD-4694; AZD4694; NAV4694; NAV 4694; NAV-4694; Flutafuranol; 2-(2-Fluoro-6-methylaminopyridin-3-yl)benzofuran-5-ol. Grade: >98%. CAS No. 1054629-49-0. Molecular formula: C14H11FN2O2. Mole weight: 258.25. | |
| AZD4721 | AZD4721, a potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2), has the potential to study inflammatory diseases. Synonyms: RIST4721; N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide; 1-Azetidinesulfonamide, N-[6-[(1R,2S)-2,3-dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl-. Grade: ≥95%. CAS No. 1418112-77-2. Molecular formula: C19H25FN4O5S2. Mole weight: 472.55. | |
| AZD4747 | AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase KRASG12C inhibitor. AZD4747 has the potential to study cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2489226-14-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-154959. | |
| AZD-4818 | AZD-4818 is a potent, orally active antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) [1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1003566-93-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15545. | |
| AZD4877 | AZD4877 is a synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which may result in the inhibition of mitotic spindle assembly. Synonyms: AZD-4877; AZD 4877; (+)-N-(3-Aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide. CAS No. 1176760-49-8. Molecular formula: C28H33N5O2S. Mole weight: 503.66. | |
| AZD-5069 | AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment. Uses: Scientific research. Category: Signaling pathways. CAS No. 878385-84-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19855. | |
| AZD-5069 | AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. AZD-5069 was shown to inhibit binding of radiolabeled CXCL8 to human CXCR2 with a pIC50 value of 9.1. Synonyms: AZD-5069; AZD 5069; AZD5069. Grade: 98%. CAS No. 878385-84-3. Molecular formula: C18H22F2N4O5S2. Mole weight: 476.51. | |
| AZD5153 | AZD5153 is a bivalent, selective, and orally active BET/BRD4 bromodomain inhibitor with an IC50 of value of 5 nM for full-length BRD4 (FL-BRD4). AZD5153 ligates two bromodomains in BRD4 simultaneously. AZD5153 can be used for the study of cancer, such as acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1869912-39-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100653. | |
| AZD 5153 | AZD5153 is a potent, selective, and orally available inhibitor of the bromodomain and extraterminal (BET). It can simultaneously bind two bromodomains in BRD4 with the IC50 value of 5 nM, which has been shown to increase antitumor activity in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B cell lymphoma. AZD5153 also shows enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency. Synonyms: AZD-5153; AZD5153; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one. Grade: 98%. CAS No. 1869912-39-9. Molecular formula: C25H33N7O3. Mole weight: 479.57. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid, a 6-hydroxy-2-naphthoic acid salt of AZD-5153, is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor possessing a bivalent binding mode (pKi = 8.3 for BRD4). Synonyms: AZD5153 6-Hydroxy-2-naphthoic acid; AZD 5153 6-Hydroxy-2-naphthoic acid; AZD-5153 6-Hydroxy-2-naphthoic acid; 6-hydroxynaphthalene-2-carboxylic acid; 4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one. CAS No. 1869912-40-2. Molecular formula: C36H41N7O6. Mole weight: 667.75. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1869912-40-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100653A. | |
| AZD5248 | AZD5248 is a dipeptidyl peptidase 1 (DPP1) inhibitor that can be used for the research of chronic obstructive lung disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1254318-44-9. Pack Sizes: 1 mg. Product ID: HY-12733. | |
| AZD5305 | AZD5305 is a potent, selective and orally active inhibitor of PARP1 with IC50 of 3 nM in wild-type A549 lung cancer cells. AZD5305 is under clinical trials for advanced solid tumor treatment. Synonyms: Saruparib; AZD 5305; AZD-5305. CAS No. 2589531-76-8. Molecular formula: C22H26N6O2. Mole weight: 406.48. | |
| AZD5305 (Saruparib) | Saruparib (AZD5305) is a highly selective and potent inhibitor of PARP1 with an IC50 of 3 nM in wild-type A549 lung cancer cells. AZD5305 shows no or minimal growth inhibitory effects in other cells (IC50s >10μM). Group: Inhibitors. CAS No. 2589531-76-8. Pack Sizes: 5mg. Product ID: S9875. Formula: C22H26N6O2. Storage Conditions: 3 years -20°C powder. | United States; Europe |
| AZD 5363 | AZD5363 is used in inhibiting the proliferation of certain tumor cell lines. Inhibits AKT1, AKT2, AKT3, P70S6K and PKA. Group: Biochemicals. Grades: Highly Purified. CAS No. 1143532-39-1. Pack Sizes: 1mg, 5mg. Molecular Formula: C21H25ClN6O2, Molecular Weight: 428.95. US Biological Life Sciences. | Worldwide |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Synonyms: AZD5363; AZD 5363; Capivasertib. Grade: 98%. CAS No. 1143532-39-1. Molecular formula: C21H25ClN6O2. Mole weight: 428.9152. | |
| AZD5363 (Capivasertib) | Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2. Group: Inhibitors. CAS No. 1143532-39-1. Pack Sizes: 5mg. Product ID: S8019. Formula: C21H25ClN6O2. Smiles: C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD 5363 dihydrochloride | AZD5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD5363 binds to and inhibits all AKT isoforms.This agent may be used as monotherapy or combination therapy for a variety of human cancers. Synonyms: (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide dihydrochloride. Grade: 99%. CAS No. 2108875-84-7. Molecular formula: C21H25ClN6O2.2HCl. Mole weight: 501.84. | |
| AZD5423 | AZD5423 is an inhaled, potent, selective, and non-steroidal glucocorticoid receptor (GR) modulator (SGRM)[1]. AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma[2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1034148-04-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108243. | |
| AZD-5423 | AZD-5423 is a nonsteroidal glucocorticoid. It is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. It was developed by AstraZeneca. Uses: Azd-5423 is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. Synonyms: AZD-5423; AZD 5423; AZD5423; UNII-641H0Q518W; 2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide. Grade: >98 %. CAS No. 1034148-04-3. Molecular formula: C25H21F4N3O3. Mole weight: 487.45. | |
| AZD5438 | AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an effective method to impair the dysregulated cell cycle that drives tumorigenesis and AZD5438 has the pharmacologic profile that provides an ideal probe to test this premise. Synonyms: AZD5438; AZD-5438; AZD 5438. Grade: 0.98. CAS No. 602306-29-6. Molecular formula: C18H21N5O2S. Mole weight: 371.45664. | |
| AZD-5438 | AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 602306-29-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-10012. | |
| AZD5462 | AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2787501-83-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148087. | |
| AZD5582 | AZD5582 is a potent IAP inhibitor, which is a dimeric compound based on the AVPI motif of Smac. AZD5582 binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). AZD5582 causes cIAP1 degradation and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro. AZD5582 was nominated as a candidate for clinical development. Synonyms: AZD5582; AZD-5582; AZD 5582. Grade: ≥98% by HPLC. CAS No. 1258392-53-8. Molecular formula: C58H78N8O8. Mole weight: 1015.31. | |
| AZD5582 | AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1258392-53-8. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12600. | |
| AZD5582 acetate | AZD5582 acetate is a potent IAP inhibitor that binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). It causes cIAP1 degradation and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro. Synonyms: AZD 5582 acetate; AZD-5582 acetate; 3,3'-[2,4-Hexadiyne-1,6-diylbis[oxy[(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]]]bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolinamide] acetate. Grade: ≥95%. Molecular formula: C60H82N8O10. Mole weight: 1075.36. | |
| AZD 5582 dihydrochloride | AZD 5582 dihydrochloride is a potent inhibitor of X-linked (XIAP) and cellular (cIAP) inhibitor of apoptosis protein. It can bind to the BIR3 domain of XIAP to prevent interaction with caspase-9. Synonyms: 3,3'-[2,4-Hexadiyne-1,6-diylbis[oxy[(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]]]bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolinamide. Grade: ≥97%. CAS No. 1883545-51-4. Molecular formula: C58H78N8O8·2HCl. Mole weight: 1088.21. | |
| AZD5582 dihydrochloride | AZD5582 dihydrochloride is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1883545-51-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-110346. | |
| AZD5597 | AZD5597 is an inhibitor of CDK with IC50 values of both 2 nM for CDK1 and CDK2. AZD5597 can inhibit the proliferation of tumor cells and has anti-tumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 924641-59-8. Pack Sizes: 5 mg; 10 mg. Product ID: HY-50914. | |
| AZD-5597 | AZD-5597 is a potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. AZD-5597 has excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel. Synonyms: AZD 5597; AZD5597; Methanone, [4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]-; [4-[[5-Fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl][(3S)-3-(methylamino)-1-pyrrolidinyl]methanone; (S)-(4-((5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(3-(methylamino)pyrrolidin-1-yl)methanone. Grade: >98%. CAS No. 924641-59-8. Molecular formula: C23H28FN7O. Mole weight: 437.52. | |
| AZD-5672 | AZD5672 is CCR5 receptor antagonist originated by AstraZeneca. In Jul 2009, Phase-II for Rheumatoid arthritis in USA was discontinued. Uses: Rheumatoid arthritis. Synonyms: AZD-5672; AZD 5672; AZD5672; UNII-61XQN688TW; (R)-N-(1-(3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide. Grade: 98%. CAS No. 780750-65-4. Molecular formula: C32H38F2N2O5S2. Mole weight: 632.79. | |
| AZD5904 | AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat. Uses: Scientific research. Category: Signaling pathways. CAS No. 618913-30-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111341. | |
| AZD-5904 | AZD-5904 is a potent orally bioavailable MPO inhibitor. It inhibited the isolated MPO enzyme with an IC50 value of 140 nM and was approximately equipotent in assays of rat and mouse MPO enzyme activity. It was used for multiple sclerosis and COPD and has been evaluated in single and multiple dose studies in healthy volunteers. Uses: Azd-5904 was used for multiple sclerosis and copd. Synonyms: AZ1, AZ 1 AZ-1; TX4; TX-4; TX 4; AZD-5904; AZD 5904; AZD5904. (S)-3-((tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one. Grade: 98%. CAS No. 618913-30-7. Molecular formula: C10H12N4O2S. Mole weight: 252.29. | |
| AZD5991 | AZD5991 is a potent and selective Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay for treatment of hematologic cancers. AZD5991 has high selectivity and affinity for Mcl-1 and is currently in clinical development. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. AZD5991 monotherapy caused apoptosis preferentially in hematological cell lines with 6/22 AML and 7/19 MM cell lines showing caspase EC50 values <100 nM. In solid tumor cell lines single agent activity was seen mostly in NSCLC and BrCa. Uses: Antineoplastic agents. Synonyms: AZD-5991; AZD 5991; AZD-5991 Racemate; 22H-9,4,8-(Metheniminomethyno)-14,20:26,23-dimetheno-10H,20H-pyrazolo[4,3-l][2,15,22,18,19]benzoxadithiadiazacyclohexacosine-32-carboxylic acid, 5-chloro-2,11,12,24,27,29-hexahydro-2,3,24,33-tetramethyl-. Grade: ≥98%. CAS No. 2143010-83-5. Molecular formula: C35H34ClN5O3S2. Mole weight: 672.26. | |
| AZD-5991 | AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2143061-81-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101533. | |
| AZD-5991 (S-enantiomer) | AZD-5991 (S-enantiomer), the less active enantiomer of AZD-5991, is an McL-1 inhibitor with an IC50 of 6.3 μM in FRET assay and a Kd of 0.98 μM in surface plasmon resonance (SPR) assay. Uses: Antineoplastic agents. Synonyms: 22H-9,4,8-(Metheniminomethyno)-14,20:26,23-dimetheno-10H,20H-pyrazolo[4,3-l][2,15,22,18,19]benzoxadithiadiazacyclohexacosine-32-carboxylic acid, 5-chloro-2,11,12,24,27,29-hexahydro-2,3,24,33-tetramethyl-, (3aS)-. Grade: ≥95%. CAS No. 2143061-82-7. Molecular formula: C35H36ClN5O3S3. Mole weight: 672.26. | |
| AZD-6126 | AZD6126 is a water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. Synonyms: AZD6126; AZD 6126; N-Acetylcochinol-O-phosphate; (5S)-5-acetamido-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-3-yl dihydrogen phosphate; N-[9,10,11-Trimethoxy-3-(phosphonooxy)-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl]ethanimidic acid. CAS No. 219923-05-4. Molecular formula: C20H24NO8P. Mole weight: 437.38. | |
| AZD6244 (Selumetinib) | Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3. Group: Inhibitors. Alternative Names: ARRY-142886. CAS No. 606143-52-6. Pack Sizes: 200mg. Product ID: S1008. Formula: C17H15BrClFN4O3. Smiles: CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD6280 | AZD6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder. Uses: Scientific research. Category: Signaling pathways. CAS No. 942436-93-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19872. | |
| AZD-6280 | AZD-6280 is a selective GABAA(α2/3) receptor modulator for the treatment of generalized anxiety disorder. Synonyms: AZD6280; UNII-B9Z1OEH19D; AZD 6280; B9Z1OEH19D; CHEMBL1783256. Grade: 98%. CAS No. 942436-93-3. Molecular formula: C20H22N4O3. Mole weight: 366.4. | |
| AZD6482 | AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1. Synonyms: KIN193; AZD6482; KIN 193; AZD 6482; KIN-193; AZD-6482. Grade: >98%. CAS No. 1173900-33-8. Molecular formula: C22H24N4O4. Mole weight: 408.45. | |
| AZD 6482 | AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: KIN-193. CAS No. 1173900-33-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10344. | |
| AZD6482 (S-isomer) | This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZD6482 also inhibited insulin-induced human adipocyte glucose uptake in vitro and IC50 value is 4.4 μm. In May 2008, AstraZeneca completed a phase I trial in Thrombosis in Sweden. In Jul 2010, Phase-I for Thrombosis in Sweden was discontinued. Uses: Thrombosis. Synonyms: AZD6482 (S-isomer); AZD 6482 (S-isomer); AZD-6482 (S-isomer); (S)-2-((1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethyl)amino)benzoic acid,1173900-33-8 (AZD6482). Grade: 98%. CAS No. 1173900-37-2. Molecular formula: C22H24N4O4. Mole weight: 408.46. | |
Our database is helping our users find suppliers everyday.
